105 completed, 26 recruiting, 25 unknown, 22 active not recruiting. 122 Phase 2, 59 Phase 1, 40 Phase 3, 4 Phase 4, 2 Early Phase 1.
Follow eribulin: new trials by email Literature Review of eribulin trials Research Report on eribulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) Trilaciclib, Eribulin - Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-11-04 | 2025-12-01 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 90 | 2026-10-31 | 2026-09-17 |
| A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers AL58805, AL8326, Eribulin - Endometrial Neoplasms, Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer Zanidatamab, Tucatinib, Capecitabine - HER 2 Positive Advanced Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | MedSIR | 24 | 2026-07-01 | 2026-04-23 |
| A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates Eribulin in Combination with Anlotinib - HER 2 Negative Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 52 | 2026-04-01 | 2026-04-09 |
| A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer SYS6010, Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) - Recurrent or Metastatic Breast Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-04-01 | 2026-02-12 |
| YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer YL202, Eribulin, Capecitabine - Locally Advanced or Metastatic Breast Cancer | Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 376 | 2026-03-17 | 2026-05-26 |
| A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation Inavolisib in Combination With Eribulin - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Hu Hai | 26 | 2026-03-15 | 2026-03-02 |
| The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis Trastuzumab Rezetecan, Chemotherapy of Physician's Choice - HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 184 | 2026-03-01 | 2026-10-15 |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) - Metastatic Breast Cancer in the Liver | Phase 2 | Recruiting | Delcath Systems Inc. | 90 | 2026-01-29 | 2026-10-19 |
| Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer Neratinib Combined with Fulvestrant and Eribulin - Brest Cancer | Phase 2 | Not yet recruiting | Xijing Hospital | 35 | 2025-12-20 | 2026-01-12 |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine - Breast Neoplasms | Phase 3 | Recruiting | BioNTech SE | 558 | 2025-10-30 | 2026-10-20 |
| Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma Zanzalintinib, Eribulin - Advanced Leiomyosarcoma, Adipocytic Sarcoma | Phase 1 | Recruiting | Washington University School of Medicine | 18 | 2025-10-22 | 2026-06-03 |
| A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma. QL1706 + Eribulin + Anlotinib + Radiotherapy - Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Fudan University | 46 | 2025-10-01 | 2025-10-03 |
| Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer Gemcitabine, Vinorelbine, Eribulin, or Utidelone - Breast Neoplasms | Phase 3 | Recruiting | Sun Yat-sen University | 192 | 2025-09-15 | 2025-12-11 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-08-04 | 2025-07-03 | |
| Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer JSKN016, Capecitabine, Paclitaxel (albumin bound) - Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 180 | 2025-06-01 | 2025-09-17 |
| A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel - HER2-low Breast Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 566 | 2025-05-15 | 2026-01-21 |
| JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC Ivarmacitinib, Camrelizumab (SHR-1210), Eribulin - Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 40 | 2024-12-01 | 2024-12-12 |
Showing 20 of 216. Sign in to see all of them.
Breast Neoplasms (119) · Triple Negative Breast Neoplasms (27) · Neoplasm Metastasis (18) · Sarcoma (18) · Neoplasms (16) · Carcinoma, Non-Small-Cell Lung (7) · Ovarian Neoplasms (6) · Brain Neoplasms (5) · Prostatic Neoplasms (4) · Carcinoma, Transitional Cell (3) · Inflammatory Breast Neoplasms (3) · Liposarcoma (3) · Urinary Bladder Neoplasms (3) · Carcinoma (2) · Carcinoma, Renal Cell (2)
Eisai Inc. (32) · National Cancer Institute (NCI) (15) · Eisai Co., Ltd. (7) · MedSIR (7) · Dana-Farber Cancer Institute (6) · Fudan University (6) · M.D. Anderson Cancer Center (6) · Eisai Limited (5) · Sun Yat-sen University (5) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Gilead Sciences (3) · Sichuan Baili Pharmaceutical Co., Ltd. (3) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (3) · AstraZeneca (2) · BioNTech SE (2)
United States (103) · China (46) · France (29) · Spain (28) · Italy (24) · United Kingdom (23) · Canada (22) · Germany (22) · South Korea (19) · Belgium (16) · Japan (15) · Netherlands (12) · Taiwan (12) · Australia (10) · Poland (10)
Dale Shuster, Ph.D. (4) · Jian Zhang (3) · Jiong Wu (3) · Sam Misir (3) · Virginia Kaklamani, MD (3) · Antonio Llombart, MD (2) · Jianli Zhao (2) · Sarmad Sadeghi (2) · Akhil Chopra (1) · Aleix Prat, MD (1) · Amanda Linz, MD (1)
PMID 20299316, PMID 21376385, PMID 24682463, PMID 25605862, PMID 27391598, PMID 33093337, PMID 40657894, PMID 15215160, PMID 15313917, PMID 15681523, PMID 15755984, PMID 16172161, PMID 16172168, PMID 17016557, PMID 17647245, PMID 18443902, PMID 18854571, PMID 19097774, PMID 19289619, PMID 19349550, PMID 19720913, PMID 20450446, PMID 20498403, PMID 20679609, PMID 21383283, PMID 21887501, PMID 21935916, PMID 21937277, PMID 21990397, PMID 22149875, PMID 23168366, PMID 24699910, PMID 24722180, PMID 24827127, PMID 25024001, PMID 25242374, PMID 26006067, PMID 26126970, PMID 26433580, PMID 26554651, PMID 26567010, PMID 26874885, PMID 27398025, PMID 28115222, PMID 28214655, PMID 28498781, PMID 28660549, PMID 28911085, PMID 29100193, PMID 29522361
2018 (4), 2023 (4), 2005 (3), 2009 (3), 2014 (3), 2017 (3), U01CA062505 (3), 2015 (2), 2016 (2), 2025 (2), N01CM00038 (2), N01CM62201 (2), N01CM62209 (2), P30CA033572 (2), UM1CA186717 (2)